Test Preparation : No special preparation required

Sample : Paraffin Blocks/Tissue in buffered formalin

Methodlogy : IHC

Description :

WHAT IS IT?

In the fields of pathology and oncology, the Immunohistochemistry (IHC) - Carcinoembryonic Antigen (CEA) test is an essential diagnostic tool. IHC is a method that uses certain antibodies to see and recognize particular proteins or antigens in tissue samples. In order to identify the presence and distribution of the CEA protein in tissues, particularly in malignant or possibly cancerous cells, the Carcinoembryonic Antigen (CEA) test is a specialized application of IHC. Normally synthesized during fetal development, CEA is a glycoprotein that is present in adults at lesser concentrations. Elevated levels of CEA can be a sign of several cancer types, most frequently colon cancer but also malignancies of the lung, breast, pancreatic, and stomach. By using CEA-specific antibodies to stain small tissue samples, the IHC-CEA test enables pathologists to visually evaluate the distribution and concentration of CEA inside the tissue. The diagnosis, cause, and extent of cancer may all be determined with the help of this information. The IHC-CEA test is essential for directing treatment choices and tracking the development of cancer, which results in more focused and efficient patient care.

WHY?

The Immunohistochemistry (IHC) - Carcinoembryonic Antigen (CEA) test is a useful tool for the detection, assessment of prognosis, and management of many malignancies' therapeutic outcomes. This test allows pathologists and oncologists to determine the presence and distribution of the Carcinoembryonic Antigen (CEA) in tissue samples. It does this by using certain antibodies that specifically target the CEA. Elevated CEA levels are frequently linked to specific malignancies, mainly colorectal cancer, but also lung, pancreatic, stomach, breast, and breast cancer. The IHC-CEA test offers vital information on the distribution and concentration of CEA in various tissues, assisting in the localization of the cancer's origin, staging, and evaluation of its aggressiveness. Making judgments regarding treatment options including surgery, chemotherapy, or targeted medicines requires knowledge of this information. The IHC-CEA test also assists in tracking the effectiveness of treatment and identifying future recurrences. The IHC-CEA test is essential for developing tailored treatment strategies, enhancing patient outcomes, and advancing the field of oncology since it provides a more accurate knowledge of the molecular properties of the tumor.

PRECAUTIONS

Follow the directions, let your doctor know about any existing illnesses, allergies, or medicines, and get enough rest before an Immunohistochemistry (IHC) - Carcinoembryonic Antigen (CEA) test. Address any emotional issues you may have and talk to your healthcare professional about them. For a successful and educational exam, working together with your medical team and following their advice is essential. This strategy guarantees accurate outcomes and a more precise diagnosis.